Catalent, the parent company of Catalent Pharma Solutions, has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for a proposed initial public offering (IPO) of its common stock. The number of shares to be offered and the price range have not yet been determined. The company intends to use the net proceeds from the IPO to repay debt, with any remaining balance to be used for general corporate purposes.

Catalent Pharma Solutions is a global provider of advanced delivery technologies and development solutions, providing worldwide clinical and commercial supply capabilities for drugs, biologics and consumer health products.